Synergy Pharma's bowel drug succeeds in key study

Dec 9 (Reuters) - Synergy Pharmaceuticals Inc said its experimental oral drug, plecanatide, met the main goal of a late-stage study on irritable bowel syndrome patients with constipation (IBS-C), according to an analysis of preliminary data.